The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease

Abstract

Rivaroxaban is a non-vitamin K antagonist oral anticoagulant that acts as a direct factor Xa inhibitor, and is widely used for the prevention and treatment of thromboembolic disorders. As further knowledge gaps are identified in thrombosis management, the rivaroxaban research program has expanded in an attempt to elucidate the wider benefits of rivaroxaban. An increased understanding of the interactions taking place within the coagulation cascade may support a broader role for rivaroxaban (2.5 mg twice daily [bid] or 5 mg bid) in the setting of vascular protection, either alone or in combination with an antiplatelet agent. The aim of this article is to describe the potential role of rivaroxaban in the context of vascular protection and provide an overview of recently completed and ongoing randomized controlled trials of rivaroxaban in the areas of stroke prevention, venous protection and vascular protection.

Keywords

atherothrombosis - coronary artery disease - stroke - rivaroxaban

• References

• 1 Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 2011; 10 (01) 61-75
• 2 Bayer AG. Xarelto Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf . Accessed February 7, 2018
• 3 Eriksson BI, Borris LC, Friedman RJ. , et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
• 4 Kakkar AK, Brenner B, Dahl OE. , et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31-39
• 5 Lassen MR, Ageno W, Borris LC. , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
• 6 Turpie AG, Lassen MR, Davidson BL. , et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-1680
• 7 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 8 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
• 9 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
• 10 Mega JL, Braunwald E, Wiviott SD. , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
• 11 Bayer AG. . Bayer Extends Clinical Investigation of Xarelto® for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer. Available at: https://www.xarelto.com/en/resources/newsfeed/bayer-extends-clinical-investigation-of-xarelto-for-the-prevention-and-treatment-of-life-threatening-blood-clots-in-patients-with-cancer/# Accessed February 7, 2018
• 12 Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31 (01) 17-28
• 13 Cortés-Beringola A, Fitzsimons D, Pelliccia A, Moreno G, Martín-Asenjo R, Bueno H. Planning secondary prevention: room for improvement. Eur J Prev Cardiol 2017; 24 (3 Suppl): 22-28
• 14 Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007; 21 (01) 1-11
• 15 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407 (6801): 258-264
• 16 Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 2015; 20 (06) 554-562
• 17 Mega JL, Braunwald E, Murphy SA. , et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013; 61 (18) 1853-1859
• 18 Berger JS, Bhatt DL, Steg PG. , et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2011; 162 (01) 98-105.e1
• 19 Bonaca MP, Creager MA, Olin J. , et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2 degrees P-TIMI 50 trial. JACC Cardiovasc Interv 2016; 9 (20) 2157-2164
• 20 Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. ; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30 (02) 192-201
• 21 Hur DJ, Kizilgul M, Aung WW, Roussillon KC, Keeley EC. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery. Am J Cardiol 2012; 110 (05) 736-740
• 22 Hussein AA, Uno K, Wolski K. , et al. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol 2011; 57 (10) 1220-1225
• 23 Gibson CM, Mehran R, Bode C. , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
• 24 Fox KF, Cowie MR, Wood DA. , et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22 (03) 228-236
• 25 Cugno M, Mari D, Meroni PL. , et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004; 126 (01) 85-92
• 26 Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103 (13) 1746-1751
• 27 Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ 2000; 320 (7229): 236-239
• 28 Zannad F, Greenberg B, Cleland JG. , et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 2015; 17 (07) 735-742
• 29 Homma S, Thompson JL, Pullicino PM. , et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366 (20) 1859-1869
• 30 Cleland JG, Findlay I, Jafri S. , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148 (01) 157-164
• 31 Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. ; HELAS Investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8 (04) 428-432
• 32 COMPASS. ClinicalTrials.gov Identifier: NCT01776424. Available at: https://ClinicalTrials.gov/show/NCT01776424 . Accessed February 7, 2018
• 33 Bosch J, Eikelboom JW, Connolly SJ. , et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol 2017; 33 (08) 1027-1035
• 34 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 35 PR Newswire. Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for Efficacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease. Available at: http://www.prnewswire.com/news-releases/phase-3-compass-study-of-xarelto-rivaroxaban-stopping-early-for-efficacy-study-meets-primary-endpoint-of-prevention-of-major-adverse-cardiac-events-in-patients-with-coronary-artery-disease-or-peripheral-artery-disease-300404477.html . Accessed February 7, 2018
• 36 VOYAGER PAD. ClinicalTrials.gov Identifier: NCT02504216. Available at: https://ClinicalTrials.gov/show/NCT02504216 . Accessed February 7, 2018
• 37 COMMANDER HF. ClinicalTrials.gov Identifier: NCT01877915. Available at: https://ClinicalTrials.gov/show/NCT01877915 . Accessed February 7, 2018
• 38 Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012; 8 (01) 129-138
• 39 Vahanian A, Alfieri O, Andreotti F. , et al; Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33 (19) 2451-2496
• 40 Nishimura RA, Otto CM, Bonow RO. , et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135 (25) e1159-e1195
• 41 Nishimura RA, Otto CM, Bonow RO. , et al; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (23) 2440-2492
• 42 Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011; 6 (09) e24964
• 43 Bahit MC, Lopes RD, Wojdyla DM. , et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol 2013; 170 (02) 215-220
• 44 Mehta RH, Dabbous OH, Granger CB. , et al; GRACE Investigators. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003; 92 (09) 1031-1036
• 45 January CT, Wann LS, Alpert JS. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1-e76
• 46 You JJ, Singer DE, Howard PA. , et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
• 47 Camm AJ, Kirchhof P, Lip GY. , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19) 2369-2429
• 48 Faxon DP, Eikelboom JW, Berger PB. , et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106 (04) 572-584
• 49 Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106 (04) 569-571
• 50 Lamberts M, Gislason GH, Olesen JB. , et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62 (11) 981-989
• 51 Lip GY, Huber K, Andreotti F. , et al; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103 (01) 13-28 . Erratum in Thromb Haemost. 2010 Sep;104(3):653
• 52 Hansen ML, Sørensen R, Clausen MT. , et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170 (16) 1433-1441
• 53 Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke 2017; 48 (04) 867-872
• 54 Perera KS, Vanassche T, Bosch J. , et al; ESUS Global Registry Investigators. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke 2016; 11 (05) 526-533
• 55 Hart RG, Diener HC, Coutts SB. , et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13 (04) 429-438
• 56 Ntaios G, Papavasileiou V, Milionis H. , et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015; 46 (08) 2087-2093
• 57 Gibson CM, Mehran R, Bode C. , et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015; 169 (04) 472-8.e5
• 58 NAVIGATE-ESUS. ClinicalTrials.gov Identifier: NCT02313909. Available at: https://clinicaltrials.gov/ct2/show/NCT02313909 . Accessed February 7, 2018
• 59 Hart RG, Sharma M, Mundl H. , et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal 2016; 1 (03) 146-154
• 60 Bayer AG. Bayer's NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms. Available at: http://press.bayer.com/baynews/baynews.nsf/id/C45F4AFB2CEFBDD0C12581B0004CF01B/%24File/2017-0301E.pdf?open&mod=06.10.2017_08:49:26 . Accessed February 7, 2018
• 61 GALILEO. ClinicalTrials.gov Identifier: NCT02556203. Available at: https://clinicaltrials.gov/ct2/show/NCT02556203 . Accessed February 7, 2018
• 62 Windecker S, Tijssen J, Giustino G. , et al. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J 2017; 184: 81-87
• 63 Prandoni P, Noventa F, Ghirarduzzi A. , et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
• 64 Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119 (01) 60-68
• 65 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
• 66 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110 (10) 2339-2346
• 67 Lyman GH, Khorana AA, Kuderer NM. , et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
• 68 Khorana AA, Yannicelli D, McCrae KR. , et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. Thromb Res 2016; 145: 51-53
• 69 Mandalà M, Falanga A, Roila F. ; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
• 70 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (02) 315-352
• 71 Gould MK, Garcia DA, Wren SM. , et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e227S-e277S
• 72 Weitz JI, Bauersachs R, Beyer-Westendorf J. , et al; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost 2015; 114 (03) 645-650
• 73 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
• 74 Janssen Pharmaceuticals, Inc. FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE). Available at: https://www.jnj.com/media-center/press-releases/fda-approves-new-10-mg-dosing-for-xarelto-rivaroxaban-to-reduce-the-continued-risk-of-venous-thromboembolism-vte . Accessed February 7, 2018
• 75 PharmaTimes online. EU OKs low-dose Xarelto to prevent recurrent VTE. Available at: http://www.pharmatimes.com/news/eu_oks_low-dose_xarelto_to_prevent_recurrent_vte_1210333 ; Accessed February 7, 2018
• 76 INVICTUS-VKA. ClinicalTrials.gov Identifier: NCT02832544. Available at: https://clinicaltrials.gov/ct2/show/NCT02832544 . Accessed February 7, 2018
• 77 Karthikeyan G, Zühlke L, Engel M. , et al. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart J 2012; 163 (04) 535-40.e1
• 78 RIVER. ClinicalTrials.gov Identifier: NCT02303795. Available at: https://clinicaltrials.gov/ct2/show/NCT02303795 . Accessed February 7, 2018
• 79 CASSINI. ClinicalTrials.gov Identifier: NCT02555878. Available at: https://ClinicalTrials.gov/show/NCT02555878 . Accessed February 7, 2018
• 80 PRO-LAPS II. ClinicalTrials.gov Identifier: NCT03055026. Available at: https://clinicaltrials.gov/ct2/show/NCT03055026 . Accessed February 7, 2018
• 81 Warwick Clinical Trials Unit. SELECT-D. Anticoagulation Therapy in SELECTeD Cancer Patients at risk of recurrence of venous thromboembolism. Available at: http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/cancer/select-d/ . Accessed February 7, 2018
• 82 Young A, Phillips J, Hancocks H. , et al. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 2016; 140 (Suppl. 01) S172-S173
• 83 CASTA-DIVA. ClinicalTrials.gov Identifier: NCT02746185. Available at: https://clinicaltrials.gov/ct2/show/NCT02746185 . Accessed February 7, 2018
• 84 CONKO-011. ClinicalTrials.gov Identifier: NCT02583191. Available at: https://ClinicalTrials.gov/show/NCT02583191 . Accessed February 7, 2018
• 85 Mantha S, Laube E, Miao Y. , et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 2017; 43 (02) 166-171
• 86 COSIMO. ClinicalTrials.gov Identifier: NCT02742623. Available at: https://clinicaltrials.gov/ct2/show/NCT02742623 . Accessed February 7, 2018
• 87 Thrombosis Research Institute. Frontline2. Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey. Available at: http://frontline2.tri-london.ac.uk/ . Accessed February 7, 2018